First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Running, not enrolling · Phase 1

Conditions studied: Extensive Stage Small Cell Lung Cancer

In brief

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Key facts

Study ID

NCT05361395

Run by

Amgen

People needed

184

Starts

2022-08-24

Expected to finish

2028-08-28

Last updated by the study team

2026-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has provided informed consent prior to initiation of any study specific activities/procedures.
• Age greater than or equal to 18 years old at the same time of signing the informed consent.
• Histologically or cytologically confirmed Extensive Stage Small Cell Lung Cancer (ES-SCLC) and no prior systemic treatment for ES-SCLC.
• Participants with prior treatment for limited-stage SCLC (LS-SCLC) are permitted.
• Eastern Cooperative Oncology Group (ECOG) 0 to 1.
• Participants with treated asymptomatic brain metastases are eligible provided they meet defined criteria.
• Adequate organ function as defined in protocol.

You may not qualify if…

• History of other malignancy within the past 2 years with exceptions.
• Major surgery within 28 days of study day 1.
• Untreated or symptomatic brain metastases and leptomeningeal disease.
• Participants who experienced recurrent grade 2 pneumonitis or severe or life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
• History of immune-related colitis.
• History or evidence of interstitial lung disease or active, non-infectious pneumonitis.
• Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
• Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment
• Participant has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint
• NOTE: Simple urinary tract infections and uncomplicated bacterial pharyngitis are permitted if responding to an active treatment and after consultation with Medical Monitor. Participants requiring oral antibiotics who have been afebrile for >24 hours, have no leukocytosis, nor clinical signs of infection are eligible. Screening for chronic infectious conditions is not required.
• History of hypophysitis or pituitary dysfunction.
• History of solid organ transplantation or allogeneic hematopoietic stem cell transplantation.
• Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study. Participants with Type I diabetes, vitiligo, psoriasis, hypo- or hyper-thyroid disease not requiring immunosuppressive treatment are permitted.

Where it is running

• University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Christiana Care Health Services — Newark, Delaware, United States
• Henry Ford Health System — Detroit, Michigan, United States
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
• New York University Grossman School of Medicine and New York University Langone Hospitals — New York, New York, United States
• The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina, United States
• Avera Cancer Institute — Sioux Falls, South Dakota, United States
• Swedish Cancer Institute Medical Oncology — Seattle, Washington, United States
• West Virginia University Health Sciences Center — Morgantown, West Virginia, United States
• Chris OBrien Lifehouse — Camperdown, New South Wales, Australia
• Universitair Ziekenhuis Antwerpen — Edegem, Belgium
• Algemeen Ziekenhuis Maria Middelares — Ghent, Belgium
• Jessa Ziekenhuis - Campus Virga Jesse — Hasselt, Belgium
• AZ Delta Campus Rumbeke — Roeselare, Belgium
• Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• CHU de Quebec Hopital de l Enfant Jesus — Québec, Quebec, Canada
• Rigshospitalet — Copenhagen, Denmark
• Centre Leon Berard — Lyon, France
• Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec — Saint-Herblain, France
• Gustave Roussy — Villejuif, France
• Universitaetsklinikum Dresden — Dresden, Germany
• Universitaetsklinikum Essen — Essen, Germany
• Universitaetsklinikum Freiburg — Freiburg im Breisgau, Germany
• Rambam Medical Center — Haifa, Israel
• Hadassah Ein-Kerem Medical Center — Jerusalem, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.